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Yttrium-90, a New Beta Emitter for Prevention of 
Post Angioplasty Restenosis: Tissue Dosimetry and 
Importance of Intraarterial Centering
Vitali Venn, Youri Popowski, Philip Urban, Phillip Nouet, Michel Rouzaud, 
Michael Schwager, John M. Kurtz, Wilhelm Rutishauser. University 
Hospital, Geneva, Switzerland
Intraarterial irradiation reduces restenosis following experimental balioon 
angioplasty. Beta irradiation has the advantages of a markedly steeper dose 
decrease in tissue and less radioprotection problems, allowing its use in 
an ordinary catheterization laboratory. We developed a dedicated 90-Yttrium 
(90Y) pure beta-emitting source, in the form of a flexible coii (diameter 0,014” , 
length 22 mm} attached to the distal end of a 0.014" thrust wire. A segmented 
balloon consisting of four interconnected compartments (Schneider-Europe, 
AG) was developed to allow for intraarterial centering of the 90Y source, The 
tissue depth curve and dose variability on the surface of 1) conventional 
angioplasty balloons and 2) the centering balloon were studied using small 
thermoluminescent dosimeters. The tissue-depth dose cun/e for standard 
2.5, 3, 3.5 and 4 mm balloons filled with contrast medium (Omnipaque 240) 
normalized to a surface dose of 10 Gy is presented in the figure. The standard 
deviations (percents of the mean) for the surface doses of 2.5, 3, 3.5, and
4 mm conventional PTC A balloons were 1.9 (13%), 5.5 (59%), 5.8 (73%), 
and 6,5 (110%) Gy, respectively. The mean, minimum and maximum doses 
on the surface of the 3.5 mm centering balloon were 8.4, 7.3, and 9,5 Gy 
(standard deviation 0.66 Gy, or 8% of the mean).
2.5 mm 
3 mm
3.5 mm 
4.0 mm 
Maan
o
DISTANCE (MM)
Conclusions: 1) The tissue dose distribution of 90Y is well suited to the 
purpose of selective irradiation of the coronary arterial wall (thickness 0.3-
0.8 mm)-for prevention of restenosis; 2) Homogeneous intramural dose 
delivery can be acheived with the help of a specially designed centering 
balloon.
4:15
Imaging of Human Atherosclerotic Lesions With 
In-111 Z2D3 Antibody Specific for Proliferating 
Smooth Muscle Cells in Human Atheroma
Pierluigi Pieri, Ignasi Carrió, Jagat Narula, Giovanni Moscatelli,
Lourdes Prat, Luciano Pedrini, Vicens Riambau, Chris Pak, Francis Chen, 
Ban-An Khaw. Bufaiini Hospital, Cesena, Italy; Hospital de Sant Pau, 
Barcelona, Spain; Scotgen, Menlo Park, CA; Northeastern University, 
Boston, MA
Radiolabeled mouse/human chimeric antibody Z2D3 specific for an antigen 
on proHferating'smooth muscle cells in human atheroma has been used to 
noninvasively visualize experimental atherosclerotic lesions in rabbits. Fur­
thermore, negative-charge polymer-mod if ¡cation of Z2D3 allowed enhanced 
target visualization with very high specific radioactivity and reduced back­
ground activity.
To evaluate its usefulness, negative charge-modified Z2D3 F (ab')2 was 
administered to 11 patients undergoing carotid endarterectomy. Each patient 
received 250 jjlg of Z2D3 labeled with 5 mCi of in-111 Lv. Serial gamma 
images, blood and urine samples were obtained for 72 H following injection. 
Carotid endarterectomy was performed within 48 H after the last imaging 
session. The sites of stenosis seen arteriographicaily were compared to 
location of the most intense antibody uptake. Endarterectomy specimens 
were imaged ex-vivo and then characterized immunohistochemically.
The concentration of the antibody was seen in all patients in the region of 
the carotid plaques. Uptake was focal and was best seen at 4 H. Intensity of 
uptake decreased over time. Whole body scans demonstrated localization in 
the kidneys, liver, and bone marrow which remained essentially unchanged.
No adverse reactions to the antibody were observed. Immunohistochemistry 
of endarterectomy specimens demonstrated specific localization of Z2D3 in 
the region of proliferating smooth muscle cells in the intima of the lesion.
The present study demonstrated the feasibility of nonEnvasive visualization 
of human atherosclerotic lesions. Further studies will be needed to optimize 
the imaging technique for potential clinical applications.
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What Causes Focal Restenosis at the Margins of 
Palmaz-Schatz Stents? A Serial Intravascular 
Ultrasound Study
Rainer Hoffman, Gary S. Mintz, Jeffrey J. Popma, Augusto D, Pichard, 
Lowell F. Satler, Kenneth M, Kent, Jennifer Griffin, Theresa Bucher,
Rolf Fuessl, Mary K. Kehoe, Donna Hunn, Debra Deforty, Martin B. Leon. 
Washington Hospital Center; Washington, DC
To understand the mechanism of restenosis at the margins of Palmaz-Schatz 
stents, we compared serial intravascular ultrasound (IVUS) studies post stent 
implantation and follow-up (5.4 ±  3*8 months) in 88 lesions and analyzed 
reference {Ref: arterial, lumen, and plaque areas (in mm2); plaque burden 
(plaque/arterial area); remodeling (A  arterial area); tissue growth (A  plaque 
area); and dissections} and stent margin {stent and intimal hyperplasia (IH) 
areas}. 29 lesions had focal restenosis involving one or both margins.
Restenosis No Restenosis P
Post-stent Ref arterial area 15.8 ± 3 .8 18.6 ± 7 .5 0.1097
lumen area 8.5 ±  3,4 10.8 ± 5 .3 0.0886
plaque burden 48 ± 1 3 4 3 ±  12 0.0868
Ref remodeling 2.2 ± 1 .8 1.2 ± 2 .4 0.0692
Stent area 8.7 ± 3 .6 10.4 ± 4 .4 0.0607
IH area within stent 5.0 ±  2.7 2.1 ± 1 .8 <  0.QQ01
Stent margin dissections were uncommon (4/88). There was no significant 
tissue growth (A plaque area) at the Ref sites or recoil (A stent area) of the 
stent margins. We conclude: Restenosis at the stent margin is common (33%) 
and is associated with implanting the edge of the stent within smaller, more 
diseased Ref vessels {smaller arterial, lumen, and stent areas; greater plaque 
burden). Superimposed Ref segment remodeling and neointimal tissue ac­
cumulation within smaller stent margins results in restenosis. These findings 
underlie the importance of anchoring edges of Palmaz-Schatz stents into 
healthy vessels with large lumens; this may require more extensive stenting 
to cover moderate proximal or distal stenoses.
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An Open Multicenter Registry to Evaluate Local 
Heparin Delivery Following Balloon Angioplasty for 
the Prevention of Restenosis: Preliminary Results
Edoardo Camenzind, Victor Legrand, Mathias Vrolix, Claude Hanet,
William Wijns, Christophe Bauters, Wim Aengevaeren, Peter den Heijer, 
Tony Gershlick, Eline Montauban van Swijndregt, Peter van der Meer,
Rein Melkert, Patrick Serruys, on behalf of the DISPATCH Investigators. 
Thoraxcenter, Erasmus University, Rotterdam, The Netherlands
Although heparin has been shown effective to prevent restenosis in ani­
mal studies, previous clinical studies have failed to show any efficacy after 
systemic administration.
Local, intracoronary heparin delivery (Dispatch™ Scimed; 1783 ±  185 IU 
during 30 ±  3 min) was successfully performed in 117 patients (79 men, 
62 ±  10 years) following balloon angioplasty. No acute cardiac event were 
observed during hospital stay. Meanwhile 43 patients (32 men, 58 ±  9 years) 
have been reviewed clinically and angiographically for 6 month follow-up: 10 
patients were symptomatic (3 unstable and 7 stable angina). Angiography 
showed in 10/43 (23%) restenosis (diameter stenosis > 50%). No aneurys­
matic dilatation at the site of heparin delivery was observed, MID measured 
by quantitative analysis system (CAAS II) in matched projections changed 
from 1.15 ±  0.36 mm (pre) through 2.03 ±  0.44 mm (post) to 1.75 ±  0.62 
mm (at 6 month follow-up).
Local heparin Matched group* p-value
Acute gain (mm) 0.90 ±  0.46 0.90 ± 0 .4 6 NS
Late loss (mm) 0.28 ± 0 .5 8 0.45 ± 0 .5 8 <0.05
* matched for vessel size, acute gain and lesion location
Nine patients (21%) required a re*PTCA and 1 patient required surgery
(2%) of the treated segment, No myocardial infarction and no death were 
observed.
Conclusion: Local heparin delivery following balloon angioplasty by means 
of the coil-balloon may reduce on longterm the incidence of restenosis and 
decrease the need for re-vascularization.
